FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973089478> ?p ?o ?g. }

• W1973089478 endingPage "135" @default.
• W1973089478 startingPage "130" @default.
• W1973089478 abstract "Background: Second-line bismuth-containing quadruple therapy is complex and frequently induces adverse effects. A triple rescue regimen containing levofloxacin is a potential alternative; however, resistance to quinolones is rapidly increasing. Aim: To evaluate the efficacy and tolerability of a second-line triple-regimen–containing levofloxacin in patients whose Helicobacter pylori eradication treatment failed and to assess whether the efficacy of the regimen decreases with time. Methods: Design: Prospective multicenter study. Patients: In whom treatment with a regimen comprising a proton-pump inhibitor, clarithromycin, and amoxicillin had failed. Intervention: Levofloxacin (500 mg bid), amoxicillin (1 g bid), and omeprazole (20 mg bid) for 10 days. Outcome: Eradication was confirmed using the 13C-urea breath test 4 to 8 weeks after therapy. Compliance/tolerance: Compliance was determined through questioning and recovery of empty medication envelopes. Incidence of adverse effects was evaluated by means of a questionnaire. Results: The study sample comprised 1000 consecutive patients (mean age, 49±15 y, 42% men, 33% peptic ulcer) of whom 97% took all medications correctly. Per-protocol and intention-to-treat eradication rates were 75.1% (95% confidence interval, 72%-78%) and 73.8% (95% confidence interval, 71%-77%). Efficacy (intention-to-treat) was 76% in the year 2006, 68% in 2007, 70% in 2008, 76% in 2009, 74% in 2010, and 81% in 2011. In the multivariate analysis, none of the studied variables (including diagnosis and year of treatment) were associated with success of eradication. Adverse effects were reported in 20% of patients, most commonly nausea (7.9%), metallic taste (3.9%), myalgia (3.1%), and abdominal pain (2.9%). Conclusions: Ten-day levofloxacin-containing therapy is an encouraging second-line strategy, providing a safe and simple alternative to quadruple therapy in patients whose previous standard triple therapy has failed. The efficacy of this regimen remains stable with time." @default.
• W1973089478 created "2016-06-24" @default.
• W1973089478 creator A5005448698 @default.
• W1973089478 creator A5011716973 @default.
• W1973089478 creator A5012587220 @default.
• W1973089478 creator A5016552830 @default.
• W1973089478 creator A5017165710 @default.
• W1973089478 creator A5020720052 @default.
• W1973089478 creator A5021684089 @default.
• W1973089478 creator A5030128117 @default.
• W1973089478 creator A5033025721 @default.
• W1973089478 creator A5037356434 @default.
• W1973089478 creator A5045576599 @default.
• W1973089478 creator A5048690854 @default.
• W1973089478 creator A5053129179 @default.
• W1973089478 creator A5058442099 @default.
• W1973089478 creator A5060490856 @default.
• W1973089478 creator A5061655096 @default.
• W1973089478 creator A5074679114 @default.
• W1973089478 creator A5075218275 @default.
• W1973089478 creator A5079912967 @default.
• W1973089478 creator A5091165049 @default.
• W1973089478 date "2013-02-01" @default.
• W1973089478 modified "2023-10-17" @default.
• W1973089478 title "Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection" @default.
• W1973089478 cites W1517613218 @default.
• W1973089478 cites W1521989023 @default.
• W1973089478 cites W1524738563 @default.
• W1973089478 cites W1563355546 @default.
• W1973089478 cites W1588080630 @default.
• W1973089478 cites W1797829304 @default.
• W1973089478 cites W1972911832 @default.
• W1973089478 cites W197707256 @default.
• W1973089478 cites W1984316482 @default.
• W1973089478 cites W1986745861 @default.
• W1973089478 cites W1989413302 @default.
• W1973089478 cites W2003405710 @default.
• W1973089478 cites W2007139524 @default.
• W1973089478 cites W2011832012 @default.
• W1973089478 cites W2012160272 @default.
• W1973089478 cites W2013134902 @default.
• W1973089478 cites W2019215575 @default.
• W1973089478 cites W2029845875 @default.
• W1973089478 cites W2037279675 @default.
• W1973089478 cites W2060551278 @default.
• W1973089478 cites W2066886904 @default.
• W1973089478 cites W2078870808 @default.
• W1973089478 cites W2078931704 @default.
• W1973089478 cites W2081846389 @default.
• W1973089478 cites W2085410680 @default.
• W1973089478 cites W2090237509 @default.
• W1973089478 cites W2099161366 @default.
• W1973089478 cites W2099267593 @default.
• W1973089478 cites W2101730203 @default.
• W1973089478 cites W2106683700 @default.
• W1973089478 cites W2114889596 @default.
• W1973089478 cites W2130429036 @default.
• W1973089478 cites W2136210283 @default.
• W1973089478 cites W2159156126 @default.
• W1973089478 cites W2162298341 @default.
• W1973089478 doi "https://doi.org/10.1097/mcg.0b013e318254ebdd" @default.
• W1973089478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22647827" @default.
• W1973089478 hasPublicationYear "2013" @default.
• W1973089478 type Work @default.
• W1973089478 sameAs 1973089478 @default.
• W1973089478 citedByCount "61" @default.
• W1973089478 countsByYear W19730894782012 @default.
• W1973089478 countsByYear W19730894782013 @default.
• W1973089478 countsByYear W19730894782014 @default.
• W1973089478 countsByYear W19730894782015 @default.
• W1973089478 countsByYear W19730894782016 @default.
• W1973089478 countsByYear W19730894782017 @default.
• W1973089478 countsByYear W19730894782018 @default.
• W1973089478 countsByYear W19730894782019 @default.
• W1973089478 countsByYear W19730894782020 @default.
• W1973089478 countsByYear W19730894782021 @default.
• W1973089478 countsByYear W19730894782022 @default.
• W1973089478 crossrefType "journal-article" @default.
• W1973089478 hasAuthorship W1973089478A5005448698 @default.
• W1973089478 hasAuthorship W1973089478A5011716973 @default.
• W1973089478 hasAuthorship W1973089478A5012587220 @default.
• W1973089478 hasAuthorship W1973089478A5016552830 @default.
• W1973089478 hasAuthorship W1973089478A5017165710 @default.
• W1973089478 hasAuthorship W1973089478A5020720052 @default.
• W1973089478 hasAuthorship W1973089478A5021684089 @default.
• W1973089478 hasAuthorship W1973089478A5030128117 @default.
• W1973089478 hasAuthorship W1973089478A5033025721 @default.
• W1973089478 hasAuthorship W1973089478A5037356434 @default.
• W1973089478 hasAuthorship W1973089478A5045576599 @default.
• W1973089478 hasAuthorship W1973089478A5048690854 @default.
• W1973089478 hasAuthorship W1973089478A5053129179 @default.
• W1973089478 hasAuthorship W1973089478A5058442099 @default.
• W1973089478 hasAuthorship W1973089478A5060490856 @default.
• W1973089478 hasAuthorship W1973089478A5061655096 @default.
• W1973089478 hasAuthorship W1973089478A5074679114 @default.
• W1973089478 hasAuthorship W1973089478A5075218275 @default.
• W1973089478 hasAuthorship W1973089478A5079912967 @default.
• W1973089478 hasAuthorship W1973089478A5091165049 @default.

• next